AAAAAA

   
Results: 1-25 | 26-37
Results: 1-25/37
THERAPY OF REFRACTORY NON-HODGKINS-LYMPHOMA (NHL) WITH I-131 LL2 (ANTI-CD22) RADIOIMMUNOTHERAPY (RIT) - RESULTS OF A REPETITIVE DOSING TRIAL
Authors: VOSE J COLCHER D BIERMAN P GOBAR L HOHENSTEIN M AUGUSTINE S GOLDENBERG D TEMPERO M ARMITAGE J
Citation: J. Vose et al., THERAPY OF REFRACTORY NON-HODGKINS-LYMPHOMA (NHL) WITH I-131 LL2 (ANTI-CD22) RADIOIMMUNOTHERAPY (RIT) - RESULTS OF A REPETITIVE DOSING TRIAL, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 13(1), 1998, pp. 7-7
THERAPY OF REFRACTORY NON-HODGKINS-LYMPHOMA (NHL) WITH I-131 LL2 (ANTI-CD22) RADIOIMMUNOTHERAPY (RIT) - RESULTS OF A REPETITIVE DOSING TRIAL
Authors: VOSE J COLCHER D BIERMAN P GOBAR L HOHENSTEIN M AUGUSTINE S GOLDENBERG D TEMPERO M ARMITAGE J
Citation: J. Vose et al., THERAPY OF REFRACTORY NON-HODGKINS-LYMPHOMA (NHL) WITH I-131 LL2 (ANTI-CD22) RADIOIMMUNOTHERAPY (RIT) - RESULTS OF A REPETITIVE DOSING TRIAL, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 13(1), 1998, pp. 45-45
MOLECULAR EPIDEMIOLOGY OF EBNA-1 SUBSTRAINS OF EBV IN POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS
Authors: GREINER TC SMIR B HAUKE R GROSS T BIERMAN P
Citation: Tc. Greiner et al., MOLECULAR EPIDEMIOLOGY OF EBNA-1 SUBSTRAINS OF EBV IN POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS, Modern pathology, 11(1), 1998, pp. 130-130
2 THIRDS OF ADULT PATIENTS (PTS) WITH LYMPHOMA ACHIEVE LONG-TERM SURVIVAL AFTER SYNGENEIC BONE-MARROW TRANSPLANTATION (BMT) - RESULTS FROM THE EBMT
Authors: SWEETENHAM JW BIERMAN P TAGHIPOUR G GRATWOHL A HAGENBEEK A GREINIX H SCHAEFER UW GOLDSTONE AH
Citation: Jw. Sweetenham et al., 2 THIRDS OF ADULT PATIENTS (PTS) WITH LYMPHOMA ACHIEVE LONG-TERM SURVIVAL AFTER SYNGENEIC BONE-MARROW TRANSPLANTATION (BMT) - RESULTS FROM THE EBMT, Bone marrow transplantation, 21, 1998, pp. 620-620
I-131 LL2 (ANTI-CD22) RADIOIMMUNOTHERAPY (RIT) OF REFRACTORY NON-HODGKINS-LYMPHOMA (NHL) - RESULTS OF A REPETITIVE DOSING TRIAL
Authors: VOSE J COLCHER D BIERMAN P LEICHNER P AKABANI G HARRISON K HOHENSTEIN M LESSER S HAMMERSHAIMB L GOLDENBERG DM TEMPERO M ARMITAGE J
Citation: J. Vose et al., I-131 LL2 (ANTI-CD22) RADIOIMMUNOTHERAPY (RIT) OF REFRACTORY NON-HODGKINS-LYMPHOMA (NHL) - RESULTS OF A REPETITIVE DOSING TRIAL, The Journal of nuclear medicine, 38(5), 1997, pp. 211-211
CLINICOPATHOLOGICAL CHARACTERISTICS OF 32 PATIENTS WITH POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS
Authors: HAUKE R GREINER T SMIR B TARANTOLO S GROSS T ANDERSON J SHAW B BIERMAN P
Citation: R. Hauke et al., CLINICOPATHOLOGICAL CHARACTERISTICS OF 32 PATIENTS WITH POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS, Blood, 90(10), 1997, pp. 3900-3900
2 THIRDS OF ADULT PATIENTS (PTS) WITH LYMPHOMA ACHIEVE LONG-TERM SURVIVAL AFTER SYNGENEIC BONE-MARROW TRANSPLANTATION (BMT) - RESULTS FROM THE EBMT
Authors: SWEETENHAM JW BIERMAN P TAGHIPOUR G GRATWOHL A HAGENBEEK A GREINIX H SCHAEFER UW GOLDSTONE AH
Citation: Jw. Sweetenham et al., 2 THIRDS OF ADULT PATIENTS (PTS) WITH LYMPHOMA ACHIEVE LONG-TERM SURVIVAL AFTER SYNGENEIC BONE-MARROW TRANSPLANTATION (BMT) - RESULTS FROM THE EBMT, Blood, 90(10), 1997, pp. 4512-4512
CYTOGENETICS PREDICT COMPLETE REMISSION RATE (CR) FOR ADULT PATIENTS WITH DE-NOVO ACUTE MYELOGENOUS LEUKEMIA (AML) TREATED WITH HIGH-DOSE CYTARABINE (HD ARA-C)
Authors: STEIN A ODONNELL MR SLOVAK ML LEE J NADEMANEE A PARKER P SNYDER D SMITH E MOLINA A SOMLO G MARGOLIN K FAHEY J BIERMAN P STEPAN D NILAND J BLUME KG FORMAN SJ
Citation: A. Stein et al., CYTOGENETICS PREDICT COMPLETE REMISSION RATE (CR) FOR ADULT PATIENTS WITH DE-NOVO ACUTE MYELOGENOUS LEUKEMIA (AML) TREATED WITH HIGH-DOSE CYTARABINE (HD ARA-C), Blood, 90(10), 1997, pp. 277-277
OUTCOMES OF PATIENTS WITH BONE-MARROW METASTASES TREATED WITH HIGH-DOSE THERAPY AND RESCUED WITH PERIPHERAL-BLOOD PROGENITOR CELLS
Authors: KESSINGER A ANDERSON J BIERMAN P BISHOP M REED E TARANTOLO S VOSE J ARMITAGE J
Citation: A. Kessinger et al., OUTCOMES OF PATIENTS WITH BONE-MARROW METASTASES TREATED WITH HIGH-DOSE THERAPY AND RESCUED WITH PERIPHERAL-BLOOD PROGENITOR CELLS, Blood, 90(10), 1997, pp. 1022-1022
LONG-TERM OUTCOME OF AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR CHRONICLYMPHOCYTIC-LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (B-CLL)
Authors: PAVLETIC Z BIERMAN P VOSE J BISHOP M WU D PIERSON J KOLLATH J KESSINGER A ARMITAGE J
Citation: Z. Pavletic et al., LONG-TERM OUTCOME OF AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR CHRONICLYMPHOCYTIC-LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (B-CLL), Blood, 90(10), 1997, pp. 1032-1032
PANCREATIC FUNGAL-INFECTIONS - A CASE-REPORT AND REVIEW OF THE LITERATURE
Authors: ROBBINS EG STOLLMAN NH BIERMAN P GRAUER L BARKIN JS
Citation: Eg. Robbins et al., PANCREATIC FUNGAL-INFECTIONS - A CASE-REPORT AND REVIEW OF THE LITERATURE, Pancreas, 12(3), 1996, pp. 308-312
OUTCOME OF HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN NON-HODGKINS-LYMPHOMA BASED THE PRESENCE OF TUMOR IN THE MARROW OR INFUSED HEMATOPOIETIC HARVEST
Authors: SHARP JG KESSINGER A MANN S CROUSE DA ARMITAGE JO BIERMAN P WEISENBURGER DD
Citation: Jg. Sharp et al., OUTCOME OF HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN NON-HODGKINS-LYMPHOMA BASED THE PRESENCE OF TUMOR IN THE MARROW OR INFUSED HEMATOPOIETIC HARVEST, Journal of clinical oncology, 14(1), 1996, pp. 214-219
ESTIMATING RATES OF DENUDATION USING COSMOGENIC ISOTOPE ABUNDANCES INSEDIMENT
Authors: BIERMAN P STEIG EJ
Citation: P. Bierman et Ej. Steig, ESTIMATING RATES OF DENUDATION USING COSMOGENIC ISOTOPE ABUNDANCES INSEDIMENT, Earth surface processes and landforms, 21(2), 1996, pp. 125-139
SANTA-FE-WORKSHOP ABSTRACTS
Authors: BIERMAN P LARSEN P CLAPP E CLARK D
Citation: P. Bierman et al., SANTA-FE-WORKSHOP ABSTRACTS, Radiocarbon, 38(1), 1996, pp. 149-173
EFFECT OF FOLLICULARITY ON OUTCOME OF HIGH-DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ASCT) FOR LARGE-CELL NON-HODGKINS-LYMPHOMA
Authors: VOSE J LYNCH J BIERMAN P ANDERSON J KESSINGER A ARMITAGE JO
Citation: J. Vose et al., EFFECT OF FOLLICULARITY ON OUTCOME OF HIGH-DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ASCT) FOR LARGE-CELL NON-HODGKINS-LYMPHOMA, Blood, 88(10), 1996, pp. 476-476
THERAPY OF REFRACTORY NON-HODGKINS-LYMPHOMA (NHL) WITH I-131 LL2 (ANTI-CD22) RADIOIMMUNOTHERAPY (RIT) - RESULTS OF A REPETITIVE DOSING TRIAL
Authors: VOSE J COLCHER D BIERMAN P LEICHNER P AKABANI G HARRISON K HOHENSTEIN M LESSER S HAMMERSHAIMB L GOLDENBERG DM TEMPERO M ARMITAGE J
Citation: J. Vose et al., THERAPY OF REFRACTORY NON-HODGKINS-LYMPHOMA (NHL) WITH I-131 LL2 (ANTI-CD22) RADIOIMMUNOTHERAPY (RIT) - RESULTS OF A REPETITIVE DOSING TRIAL, Blood, 88(10), 1996, pp. 2258-2258
CHLVPP THERAPY FOR HODGKINS-DISEASE - EXPERIENCE OF 960 PATIENTS
Authors: ANDERSON JR ARMITAGE JO VOSE JM BIERMAN P WEISENBURGER D CUNNINGHAM D OBRIEN MER MIDDLETON G WEBB A MEAD GM WHITEHOUSE JMA PROCTOR SJ
Citation: Jr. Anderson et al., CHLVPP THERAPY FOR HODGKINS-DISEASE - EXPERIENCE OF 960 PATIENTS, Annals of oncology, 6(2), 1995, pp. 167-172
HEMATOPOIETIC GROWTH-FACTORS AFTER HLA-IDENTICAL ALLOGENEIC BONE-MARROW TRANSPLANTATION IN PATIENTS TREATED WITH METHOTREXATE-CONTAINING GRAFT-VS.-HOST DISEASE PROPHYLAXIS
Authors: MARTINALGARRA S BISHOP MR TARANTOLO S COWLES MK REED E ANDERSON JR VOSE JM BIERMAN P ARMITAGE JO KESSINGER A
Citation: S. Martinalgarra et al., HEMATOPOIETIC GROWTH-FACTORS AFTER HLA-IDENTICAL ALLOGENEIC BONE-MARROW TRANSPLANTATION IN PATIENTS TREATED WITH METHOTREXATE-CONTAINING GRAFT-VS.-HOST DISEASE PROPHYLAXIS, Experimental hematology, 23(14), 1995, pp. 1503-1508
BE-10 AND AL-26 EVIDENCE FOR EXCEPTIONALLY LOW RATES OF AUSTRALIAN BEDROCK EROSION AND THE LIKELY EXISTENCE OF PRE-PLEISTOCENE LANDSCAPES
Authors: BIERMAN P TURNER J
Citation: P. Bierman et J. Turner, BE-10 AND AL-26 EVIDENCE FOR EXCEPTIONALLY LOW RATES OF AUSTRALIAN BEDROCK EROSION AND THE LIKELY EXISTENCE OF PRE-PLEISTOCENE LANDSCAPES, Quaternary research, 44(3), 1995, pp. 378-382
EVIDENCE SUGGESTING THAT METHODS OF ROCK-VARNISH CATION-RATIO DATING ARE NEITHER COMPARABLE NOR CONSISTENTLY RELIABLE - REPLY
Authors: BIERMAN P GILLESPIE A
Citation: P. Bierman et A. Gillespie, EVIDENCE SUGGESTING THAT METHODS OF ROCK-VARNISH CATION-RATIO DATING ARE NEITHER COMPARABLE NOR CONSISTENTLY RELIABLE - REPLY, Quaternary research, 43(2), 1995, pp. 274-276
PRIMARY CNS LYMPHOMA - THE CELLULAR IMMUNE-RESPONSE OF THE HOST
Authors: BASHIR RM BIERMAN P HOCHBERG FH
Citation: Rm. Bashir et al., PRIMARY CNS LYMPHOMA - THE CELLULAR IMMUNE-RESPONSE OF THE HOST, Neurology, 45(4), 1995, pp. 452-452
ESTIMATING EROSION RATES AND EXPOSURE AGES WITH CL-36 PRODUCED BY NEUTRON-ACTIVATION
Authors: BIERMAN P GILLESPIE A CAFFEE M ELMORE D
Citation: P. Bierman et al., ESTIMATING EROSION RATES AND EXPOSURE AGES WITH CL-36 PRODUCED BY NEUTRON-ACTIVATION, Geochimica et cosmochimica acta, 59(18), 1995, pp. 3779-3798
LYMPHOMA PATIENTS WHO REQUIRE PLATELET TRANSFUSIONS DURING BLOOD STEM-CELL COLLECTION HAVE SLOWER PLATELET RECOVERY AFTER HIGH-DOSE THERAPYAND AUTOTRANSPLANT
Authors: KESSINGER A ANDERSON J BISHOP M VOSE J BIERMAN P ARMITAGE JO
Citation: A. Kessinger et al., LYMPHOMA PATIENTS WHO REQUIRE PLATELET TRANSFUSIONS DURING BLOOD STEM-CELL COLLECTION HAVE SLOWER PLATELET RECOVERY AFTER HIGH-DOSE THERAPYAND AUTOTRANSPLANT, Blood, 86(10), 1995, pp. 397-397
CLINICAL OUTCOME OF PERIPHERAL-BLOOD STEM-CELL SUPPORT
Authors: KESSINGER A ARMITAGE J BIERMAN P BISHOP M JOSHI S REED E SHARP G TALMADGE J VOSE J
Citation: A. Kessinger et al., CLINICAL OUTCOME OF PERIPHERAL-BLOOD STEM-CELL SUPPORT, Medical oncology, 11(2), 1994, pp. 43-46
ANALYSIS OF PREDICTORS FOR GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) MOBILIZED PERIPHERAL STEM-CELL YIELD
Authors: WATANABE T BISHOP MR ANDERSON J PETERSEN K JACKSON J VOSE J BIERMAN P ARMITAGE J REED E TARANTOLO S KESSINGER A
Citation: T. Watanabe et al., ANALYSIS OF PREDICTORS FOR GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) MOBILIZED PERIPHERAL STEM-CELL YIELD, Experimental hematology, 22(8), 1994, pp. 781-781
Risultati: 1-25 | 26-37